MINNEAPOLIS, July 7 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (AMEX:UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, highlighted today presentations, workshops and posters focusing on its solutions at the 34th Annual Meeting of the International Urogynecological Association (IUGA), June 16-20 in Como, Italy. Urgent PC presentations at the IUGA annual meeting included: -- "Peripheral Tibial Neurostimulation (PTNS) (Urgent PC) Versus Tolterodine (Detrusitol) In the Treatment Of Women With Urge Urinary Incontinence and Urge Symptoms," presented by Oliver Preyer, M.D. of the Department of Obstetrics and Gynecology at the University of Vienna, Vienna, Austria, demonstrates Urgent PC has comparable performance to Tolterodine with a significantly lower rate of side effects. -- "The Effects of Percutaneous Tibial Nerve Stimulation Therapy (Neuromodulation) On Quality Of Life Of Patients With Chronic Pelvic Pain," was presented in a poster by S.G. Bayrak, M.D. of Istanbul University, Istanbul, Turkey, showing the treatment contributing to the quality of life of women with chronic pelvic pain by decreasing the intensity of pain (this indication is not approved in the United States). -- A presentation by Dr. Enrico Finazzi Agro of the Department of Urology at Tor Vergata University in Rome, Italy, featured a comparative effectiveness study of 35 patients treated by Uroplasty's Urgent PC system or a placebo. The study titled "Percutaneous Tibial Nerve Stimulation (PTNS) Effects On Urge Incontinence Patients Are Not Caused By A Placebo Effect: A Double Blind, Placebo Controlled Study" found urgency and frequency decreased by more than 50 percent for 64.7 percent of patients treated with Urgent PC. No patients were considered to have responded to the placebo. "The 2009 Annual IUGA Meeting represents a further accumulation of clinical evidence from leading physicians around the world supporting the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms often associated with overactive bladder," said David Kaysen, President and CEO of Uroplasty, Inc. "As this clinical evidence continues to expand, we will be presenting this data to the medical directors of U.S. payers as part of our effort to build awareness for reimbursement and eventually apply for a unique CPT code for PTNS here in the U.S. In addition to Urgent PC, Macroplastique, our 'Gold Standard' bulking agent for the treatment of adult female stress urinary incontinence, was highlighted in several podium and poster presentations and workshops." Macroplastique presentations at the IUGA annual meeting included: -- "A Cost Effective Approach To The Mid-Urethra: An Economic Analysis Of The Use Of Bulking Agents And Mid Urethral Tapes," presented by Dudley Robinson, M.D. of King's College Hospital in London, England. The findings supported the use of Macroplastique or retropubic mid-urethral tape as cost effective treatments for stress urinary incontinence and suggested Macroplastique may offer additional savings in terms of cost to the healthcare system. -- "Transurethral Injection OF Bulking Agent For The Treatment OF Recurrent Or Persistent Female Stress Urinary Incontinence After Mid-Urethral Sling," was presented in a poster by Dr. Y. Lee of Samsung Medical Center of Sungkyunkwan University School of Medicine, Seoul, South Korea, showing use of Macroplastique for a failed mid-urethral sling produces a high patient satisfaction rate and the procedure is minimally invasive with no significant complications. Treatment with Macroplastique could be an option for selected patients who have failed a mid-urethral sling with co-morbidity, operative risks, and for patients who want to avoid another surgery. In addition to these various presentations, a workshop entitled "Urethral Bulking Agents For Minimally Invasive Treatment of Stress Urinary Incontinence," chaired by Linda Cardozo, M.D. of King's College Hospital in London, England, drew a large physician audience. Macroplastique was highlighted and reviewed by the physician panel, with a significant number of positive references to safety and efficacy compared to other bulking agents. Uroplasty also sponsored a hands-on workshop where physician attendees were able to work with, and learn how to properly use, both Urgent PC and Macroplastique alongside physician experts in the use of the two products. This session drew a large audience of potential new users of both Urgent PC and Macroplastique and received positive reviews from the attendees. "All in all, this 34th Annual IUGA Meeting was a significant success for Uroplasty," concluded Mr. Kaysen. "Both Urgent PC and Macroplastique were highlighted in numerous venues which drove significant physician traffic to our exhibit booth generating a large number of sales leads for both our international and U.S. businesses." About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent(R) PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB). We also offer Macroplastique(R) Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com/. Forward-Looking Information This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT reimbursement code from the AMA for Urgent PC treatments, and that even if we succeed at obtaining a CPT code third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses. We further cannot assure that reimbursement or other issues will not further impact our fiscal 2010 results. For Further Information: Uroplasty, Inc. EVC Group David Kaysen, President and CEO, or Doug Sherk (Investors) Medi Jiwani, Vice President, CFO, and Treasurer, 415.896.6820 952.426.6140 Chris Gale (Media) 646.201.5431 DATASOURCE: Uroplasty, Inc. CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors, Doug Sherk, +1-415-896-6820, or Media, Chris Gale, +1-646-201-5431, both of EVC Group, for Uroplasty, Inc. Web Site: http://www.uroplasty.com/

Copyright